OncoMatch/Clinical Trials/NCT07201519
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
Is NCT07201519 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Hepatic Artery Infusion Pump (HAIP) and Systemic Chemotherapy Standard of Care for colorectal cancer metastatic.
Treatment: Hepatic Artery Infusion Pump (HAIP) · Systemic Chemotherapy Standard of Care · Standard Of Care targeting driver mutations — The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable intrahepatic cholangiocarcinoma. The main questions it aims to answer are: * safety and feasibility of installing a pump that deliveries chemotherapy to the hepatic artery (the blood vessel that supplies blood to the liver) * help learn more about the safety of patients having pump refills at home or a local clinic versus having it routinely done at the hospital Participants will have surgery to install a pump which is a standard surgical procedure. After surgery, participants will select to either receive treatment at the hospital facility or with a community oncologist that will provide cancer care to participants close to home, rather than in a large hospital or academic medical center. The main treatment on study will last about 3-4 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Cholangiocarcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Exception: Prior radiation therapy to the pelvis is acceptable
Prior radiation to the liver, including external beam, SBRT, Y90
Lab requirements
Blood counts
absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL; HGB > 8 g/dL; INR <= 1.5
Kidney function
Creatinine < 1.5 mg/dL
Liver function
Total Bilirubin <= 1.5 mg/dL; AST/ALT < 5 x institutional upper limit of normal (ULN)
Lab Values <= 14 days prior to study enrollment: absolute neutrophil count >= 1,500/mcL Total Bilirubin <= 1.5 mg/dL AST/ALT < 5 x institutional upper limit of normal (ULN) Platelets >= 100,000/mcL Creatinine < 1.5 mg/dL HGB > 8 g/dL INR <= 1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kentucky · Lexington, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify